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OBJECTIVE
This study tested the hypothesis that intensive treatment in the Action to Control
Cardiovascular Risk in Diabetes (ACCORD) trial disproportionately produced ad-
verse outcomes in patients with diabetes with a high hemoglobin glycation index
(HGI = observed HbA1c 2 predicted HbA1c).
RESEARCH DESIGN AND METHODS
ACCORD was a randomized controlled trial of 10,251 patients with type 2 diabetes
assigned to standard or intensive treatment with HbA1c goals of 7.0% to 7.9% (53 to
63mmol/mol) and less than 6% (42mmol/mol), respectively. In this ancillary study, a
linear regression equation (HbA1c = 0.0093 fasting plasma glucose [FPG] [mg/dL] +
6.8) was derived from 1,000 randomly extracted participants at baseline. Baseline
FPG values were used to calculate predicted HbA1c and HGI for the remaining 9,125
participants. Kaplan-Meier and Cox regression were used to assess the effects of
intensive treatment on outcomes in patients with a low, moderate, or high HGI.
RESULTS
Intensive treatment was associated with improved primary outcomes (composite
of cardiovascular events) in the low (hazard ratio [HR] 0.75 [95% CI 0.59–0.95]) and
moderate (HR 0.77 [95% CI 0.61–0.97]) HGI subgroups but not in the high
HGI subgroup (HR 1.14 [95% CI 0.93–1.40]). Higher total mortality in intensively
treated patients was confined to the high HGI subgroup (HR 1.41 [95% CI 1.10–
1.80]). A high HGI was associated with a greater risk for hypoglycemia in the
standard and intensive treatment groups.
CONCLUSIONS
HGI calculated at baseline identified subpopulations in ACCORD with harms or
benefits from intensive glycemic control. HbA1c is not a one-size-fits-all indicator
of blood glucose control, and taking this into account when making management
decisions could improve diabetes care.
The purpose of this ancillary study was to determine if the risk for diabetes com-
plications in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) glyce-
mia trial differed among individuals with lower or higher HbA1c levels than predicted
by fasting plasma glucose (FPG). ACCORD participants were middle-aged and older
people with type 2 diabetes and established cardiovascular disease (CVD) or known
cardiovascular risk factors (1). The trial tested whether intensive treatment
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targeting HbA1c levels of less than 6%
(42 mmol/mol) would reduce the rate of
cardiovascular events compared with a
strategy targeting HbA1c levels between
7.0% and 7.9% (53 and 63 mmol/mol).
This hypothesiswas not supported: Inten-
sive treatment failed to improve primary
cardiovascular outcomes and was instead
associated with 22% greater total mortal-
ity compared with standard treatment.
The ACCORD trial thus demonstrated
that increased mortality was a previously
unrecognized harm of intensive glucose-
lowering therapy in high-risk patients
with type 2 diabetes. Although symptom-
atic severe hypoglycemia was associated
with an increased risk of death in the in-
tensive and standard treatment groups,
differences in HbA1c or rates of hypogly-
cemia between the two groups did not
explain the greater mortality observed
in the intensive-treatment group (2).
Treating patients with diabetes with
drugs that lower blood glucose levels in-
herently increases the risk for hypoglyce-
mia. Intensively treating patients with
diabetes to a low HbA1c target implicitly
assumes that all patients will have roughly
the same blood glucose level when they
reach the target. Miller et al. (3) paradox-
ically reported that ACCORD participants
with higher HbA1c levels had greater risk
for hypoglycemia. If HbA1c were an unbi-
ased estimate of blood glucose, this ob-
servation would incongruously suggest
that participants with higher blood glu-
cose levels had greater risk for hypoglyce-
mia. Numerous studies have shown,
however, that some patients with diabe-
tes have HbA1c levels that are persistently
lower or higher than predicted compared
with other individuals with similar blood
glucose levels (4–10).
We reasoned that intensive treatment
to a one-size-fits-all HbA1c target of less
than 6% (42 mmol/mol) may have inad-
vertently and disproportionately pro-
duced adverse outcomes in a subgroup
of ACCORD patients with diabetes with
lower blood glucose levels than their
HbA1c would predict. To test this hypoth-
esis, we used the hemoglobin glycation
index (HGI) to identify ACCORD partici-
pants with incongruous HbA1c and FPG
at baseline. HGI is the calculated differ-
ence between an individual’s observed
HbA1c and a predicted HbA1c derived by
inserting the individual’s blood glucose
concentration into a population regression
equation describing the linear relationship
between HbA1c and blood glucose (HGI =
observed HbA1c 2 predicted HbA1c) (4,9).
Assessment of HGI in the Diabetes Con-
trol and Complications Trial (DCCT)
showed that patients with type 1 diabetes
with a highHGI had a threefold greater risk
for retinopathy and a sixfold greater risk
for nephropathy (6). Most prior HGI re-
search calculated predicted HbA1c based
on mean blood glucose (self-monitored
(4,9), timed profiles (6), or continuous
glucose monitoring (11)). HGIs calculated
using all glucose data downloaded from
patient meters were highly correlated
with HGIs calculated using only prebreak-
fast glucose data (4). The feasibility of us-
ing FPG to calculate the HGI in patients
with type 2 diabetes was previously pro-
posed (12). The glycation gap developed
by Cohen et al. (5) is calculated in exactly
the sameway as HGI except fructosamine
replaces directly measured glucose for
obtaining a predictedHbA1c. Several stud-
ies have shown that patients with type 2
diabetes with a high glycation gap have
greater risk for microvascular or macro-
vascular complications (5,10,13,14). HGI
and theglycationgap are strongly positively
correlated, which suggests they reflect the
same biological phenomenon (15).
Patients with diabetes with low and
high HGI have HbA1c levels that are lower
or higher than predicted, respectively,
compared with other patients with simi-
lar blood glucose levels.We hypothesized
that intensive treatment produced dis-
proportionately lower blood glucose lev-
els and increased hypoglycemia in the
subgroup of ACCORD participants with a
highHGI. This could explain the otherwise
paradoxical results reported by Miller
et al. (3). Also, higher baseline HbA1c
and higher average on-treatment HbA1c
were both strong predictors of mortality
associated with intensive treatment in
ACCORD (16,17). Because HGI was asso-
ciated with increased complications risk
in patients with type 1 diabetes in the
DCCT, we also hypothesized that pa-
tients with type 2 diabetes with high
HGI in ACCORD might also have a
greater risk for primary cardiovascular
outcomes, total mortality, and micro-
vascular disease.
RESEARCH DESIGN AND METHODS
This research was approved by the insti-
tutional review boards at the Louisiana
State University Health Sciences Center
and Children’s Hospital, New Orleans, LA.
ACCORD Study Design
ACCORD was a multicenter, randomized
clinical trial that used a double 2 3 2
factorial design to incorporate interven-
tion trials for glycemia, hyperlipidemia,
and hypertension. The lipid intervention
trial tested in 5,518 participants the hy-
pothesis that a hypolipidemic agent
would improve outcomes in subjects
with good glycemic control. The blood
pressure intervention trial tested in the
remaining 4,733 participants the hypoth-
esis that a therapeutic strategy that
targets a systolic blood pressure of
,120 mmHg will reduce the rate of
CVD events compared with a strategy
that targets a systolic blood pressure of
,140 mmHg. All participants enrolled in
the ACCORD trial had type 2 diabetes and
had experienced a prior cardiovascular
event or had other evidence of high risk
for CVD. Median follow-up time was 5.0
years (mean 5.0; range 0.01–8.4). The ra-
tionale, study design, inclusion criteria,
and other details of the ACCORD trial
are described elsewhere (1,18–20).
Theglycemia intervention trial included
all 10,251ACCORDparticipants,whowere
randomly assigned at baseline to a stan-
dard treatment group or an intensive
treatment group. Any antihyperglycemic
agent or combination of agents approved
by regulatory authorities could be used
as considered appropriate to achieve
protocol-mandated target HbA1c levels
of 7.0% to 7.9% (53 to 63 mmol/mol) in
the standard treatment group, or less
than 6.0% (42 mmol/mol) in the inten-
sive treatment group. During the trial,
excess mortality was demonstrated at
3.5 years of average follow-up, at which
time all participants in the intensive
treatment group were converted to the
standard treatment regimen (20). Data
for this ancillary study were obtained
from the ACCORD coordinating center
on all enrolled participants. Only data
from participants with FPG and HbA1c
recorded at baseline (n = 10,125) were
used in these analyses.
Primary and Secondary Outcomes
The prespecified primary outcome for
ACCORD was a composite of the first oc-
currence of nonfatal myocardial infarction
(MI), nonfatal stroke, or death from cardio-
vascular causes (18). Causes of cardiovas-
cular death included fatal MI, congestive
heart failure, documented arrhythmia,
death after invasive cardiovascular
1068 HGI Subgroup Analysis of ACCORD Diabetes Care Volume 38, June 2015
interventions, death after noncardiovascu-
lar surgery, fatal stroke, unexpected death
due to ischemic CVDoccurring less than 24
h after the onset of symptoms, and death
due to other vascular diseases such as pul-
monary emboli or abdominal aortic aneu-
rysm rupture. Death from any cause was
one of several prespecified secondary
outcomes (1). Primary and secondary
outcomes were assessed from baseline
through the last set of scheduled study
visits (March–June 2009) (20).
Definition of Severe Hypoglycemia
Symptomatic, severe hypoglycemia re-
quiring any assistance was defined as an
episode of hypoglycemia with a docu-
mented blood glucose concentration of
less than 50mg/dL (2.8 mmol/L) in which
the participant reported receiving medi-
cal care or assistance from another indi-
vidual or recovery with carbohydrate
treatment. Symptomatic, severe hypogly-
cemia requiring medical assistance was
defined as an episode of hypoglycemia
in which the participant received care
at a hospital or emergency department
or frommedical personnel. Hypoglycemia
assessment includedhypoglycemia events
from baseline up to the transition period
when intensive glycemic intervention was
terminated (February 2008).
Deriving HGI from the HbA1c Versus
FPG Regression Equation
Baseline FPG and HbA1c data from a ran-
dom subsample of 1,000 ACCORD par-
ticipants were used to estimate the
linear relationship between FPG and
HbA1c in the study population. A pre-
dicted HbA1c was calculated for the re-
maining 9,125 participants by inserting
the baseline FPG into the subsample lin-
ear regression equation (HbA1c = 0.009
FPG [mg/dL] + 6.8). Baseline HGI was
calculated by subtracting the predicted
HbA1c from the observed HbA1c. The
9,125 participants were then assigned
to low,moderate, or high HGI subgroups
based on baseline HGI and HGI cut
points that divided the population
into three equally sized subgroups (low
HGI # 20.520 [n = 3,041], 33.3%; mod-
erate HGI 20.520 to 0.202 [n = 3,042],
33.3%; high HGI .0.202 [n = 3,042],
33.3%). The use of a tertile classification
system is by convention for consistency
with previous HGI studies. We compared
HGI classifications using simple linear re-
gression with HGI classifications based
on cubic spline regression and observed
more than 90% identity. We chose the
linear regression model because this
approach is simpler and has precedent.
Statistical Analysis
Baseline characteristics and other vari-
ables were compared among low, mod-
erate, and high HGI subgroups. Group
comparisons used ANOVA or Kruskal-
Wallis tests for normally distributed and
nonnormally distributed continuous vari-
ables, respectively, and x2 tests were
used for categorical variables. Kaplan-
Meier curves and log-rank tests were
used to compare the distribution of
time to first event. Post hoc analyses
were performed to compare risk of pri-
mary outcomes, total mortality, and hy-
poglycemia between the intensive and
standard glycemia treatment groups and
among HGI subgroups with adjustment
for covariates. Hazard ratios and 95% CI
were determined by stratified Cox pro-
portional hazards regression models.
Tests of statistical significancewere based
on a two-tailed type 1 error at P , 0.05.
The interaction term of HGI subgroup
with glycemia treatment was added to
each model, and a likelihood ratio test
was applied. Whenever the interaction
test did notmeet the criteria for statistical
significance, a Bonferroni correction for
multiple comparisons was applied when
evaluating the effect of treatment by sub-
group. Proportional hazards assumptions
were assessed by cumulative sums mar-
tingale residuals over follow-up times us-
ing Kolmogorov-type supremum tests
and no violation was found.
Covariates included baseline charac-
teristics, study location among the seven
clinical-center networks, and for other
ACCORD intervention assignments (the
blood pressure trial, assignment to the
intensive blood pressure intervention
group, or the lipid trial, assignment to re-
ceive fibrate in the lipid trial). Sensitivity
analyses were performed to determine
hazard ratio stability after including inter-
vention assignments in the Cox model as
stratifying factors rather than as covari-
ates. Baseline characteristics were age,
sex, ethnicity, education level, medical
history (smoking history, duration of di-
abetes, retinopathy detected at baseline,
history of CVD, high risk of congestive
heart failure, evidence of significant ath-
erosclerosis, albuminuria), and laboratory
and clinical measures at baseline (FPG,
diastolic blood pressure, estimated
glomerular filtration rate, LDL-cholesterol,
HDL-cholesterol, and triglycerides). Out-
comes based on Cox regression models
were similar to those obtained using logis-
tic regression. We used Cox regression in
reporting our results to account for the fact
that ACCORD participants were monitored
for different lengths of time, leading to a
changingdenominatorover time that is not
adequately modeled by the constant aver-
age denominator imposed by the logistic
model. Statistical analyseswere performed
using SAS 9.3 or STATA 13 software.
RESULTS
Figure 1C shows the linear relationship
between HbA1c and FPG in the ACCORD
population at baseline. Figure 1A and B
shows that the frequency distribution of
HbA1c wasmarkedly different in the low,
moderate, and high HGI subgroups. In
contrast, FPG distribution was similar
among the subgroups. Selected baseline
demographic, biochemical, and clinical
characteristics are compared among
the HGI subgroups in Table 1. Of
Figure 1—Assessment of HbA1c and FPG at
baseline. The low, moderate, and high HGI
subgroups have green, blue, or red lines, re-
spectively. A: Distribution of HbA1c by HGI
subgroup. B: Distribution of FPG by HGI sub-
group. C: The red dotted line is the simple
linear population regression line.
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particular note, there were dispropor-
tionately more black and Hispanic par-
ticipants and fewer white participants
in the high HGI subgroup. Furthermore,
high HGI participants were younger,
had longer duration of diabetes, were
more likely to already have retinopathy
and a history of albuminuria at base-
line, and were more likely to have
Table 1—Baseline characteristics of ACCORD participants by HGI subgroup
Low HGI Moderate HGI High HGI
Variablea n = 3,041 n = 3,042 n = 3,042 P valueb
HbA1c (%) 7.4 6 0.5 8.1 6 0.5 9.4 6 0.9 ,0.001
Median HbA1c (%) 7.4 8.1 9.2
HbA1c (mmol/mol) 57.4 6 18.0 65.0 6 18.0 79.2 6 13.7
FPG (mg/dL) 178.5 6 52.3 169.0 6 51 178.3 6 64.2 ,0.001
FPG (mmol/L) 9.9 6 2.9 9.4 6 2.8 9.9 6 3.6
HGI (%) 20.961 6 0.4 20.183 6 0.2 0.996 6 0.7 ,0.001
Age (years) 62.6 6 6.8 62.7 6 6.9 61.5 6 6.8 ,0.001
Median [IQR] duration of diabetes (years) 8 [10] 10 [10] 10 [11] ,0.001
Female sex 1,072 (35.3) 1,196 (39.3) 1,235 (40.6) ,0.001
Race or ethnic group (group %) ,0.001
White 2,148 (37.6) 1,957 (34.3) 1,606 (28.1)
Black 375 (21.7) 551 (31.9) 799 (46.3)
Hispanic 162 (24.9) 211 (32.5) 277 (42.6)
Other 356 (34.3) 323 (31.1) 360 (34.6)
Education ,0.001
Less than high school 377 (12.4) 438 (14.4) 523 (17.2)
High school graduate 773 (25.4) 800 (26.3) 825 (27.1)
Some college 1,017 (33.5) 1,035 (34.1) 950 (31.3)
College degree or higher 872 (28.7) 767 (25.2) 742 (24.4)
Cigarette smoking status ,0.01
Current 399 (13.1) 437 (14.4) 452 (14.9)
Former 1,415 (46.6) 1,348 (44.3) 1,271 (41.9)
Never 1,223 (40.3) 1,255 (41.3) 1,314 (43.3)
Alcohol use 798 (26.3) 755 (24.8) 640 (21.1) ,0.001
Insulin use 835 (27.5) 1,036 (34.1) 1,321 (43.4) ,0.001
Metformin use 1,887 (62.1) 1,877 (61.7) 1,681 (55.3) ,0.001
Sulfonylurea use 1,576 (51.8) 1,584 (52.1) 1,433 (47.1) ,0.001
Thiazolidinedione use 595 (19.6) 645 (21.2) 538 (17.7) 0.025
History of hypertension 2,856 (93.9) 2,864 (94.2) 2,837 (93.3) 0.33
Previous CVD 1,014 (33.3) 1,114 (36.6) 1,085 (35.7) 0.02
High risk of heart failure 75 (2.5) 70 (2.3) 69 (2.3) 0.86
History of albuminuria 944 (31.0) 990 (32.5) 1,133 (37.3) ,0.001
History of left ventricular hypertrophy 125 (4.1) 107 (3.5) 151 (5) 0.02
History of arterial stenosis 141 (4.6) 158 (5.2) 157 (5.2) 0.53
Retinopathy at baseline 697 (22.9) 819 (26.9) 883 (29.0) ,0.001
Neuropathy at baseline 1,889 (62.2) 1,951 (64.3) 1,920 (63.1) 0.25
Serum creatinine (mg/dL) 0.9 6 0.2 0.9 6 0.2 0.9 6 0.2 0.12
Estimated GFR (mL/min/1.73 m2) 89.7 6 27.8 90.8 6 24.8 92.8 6 29 ,0.001
Cholesterol (mg/dL)
Total 180.3 6 39.5 182.3 6 41.6 187 6 44 ,0.001
LDL 101.1 6 32 104.4 6 33.7 108.6 6 35.3 ,0.001
HDL
Men 38.6 6 9.8 38.2 6 8.9 39.0 6 10.0 ,0.001
Women 46.7 6 12.0 46.7 6 12.7 47.9 6 13.1 ,0.001
Median [IQR] triglycerides (mg/dL) 160 [126] 155 [120] 149 [122] ,0.001
Blood pressure (mmHg)
Diastolic 74.8 6 10.7 74.3 6 10.6 75.4 6 10.7 ,0.001
Systolic 136 6 16.6 136.2 6 17.1 136.8 6 17.6 0.21
BMI (kg/m2) 32.2 6 5.4 32.3 6 5.4 32.2 6 5.6 0.56
Waist circumference (cm) 107 6 13.8 107.1 6 13.9 106.4 6 14.1 0.15
GFR, glomerular filtration rate; IQR, interquartile range. aUnless otherwise noted, values are means6 SD for continuous variables or number (%) for
categorical variables. bOverall differences between HGI groups using ANOVA, Kruskal-Wallis tests, or x2 tests.
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used insulin before the start of the
study.
After 1 year of standard (Fig. 2A) or
intensive (Fig. 2B) treatment, mean
HbA1c remained significantly different
(P , 0.001) between HGI subgroups
and was highest in the high HGI sub-
group. In contrast, the mean FPG was
significantly lower (P , 0.001) in the
moderate and high HGI subgroups after
1 year of standard treatment (Fig. 2A)
andwas not different (P. 0.05) between
HGI subgroups after 1 year of intensive
treatment (Fig. 2B). The number of par-
ticipants above or below theHbA1c inten-
sification thresholds varied after 1 year in
the standard treatment arm: 43.0% of
high HGI participants remained above
the 8% (64 mmol/mol) intensification
threshold compared with only 30.6% of
moderate and 21.9% of low HGI partici-
pants. After 1 year in the intensive treat-
ment arm, 88.7% of high HGI participants
remained above the 6% (42 mmol/mol)
intensification threshold compared with
83.9% of moderate and 72.7% of low HGI
participants. Barring mitigating circum-
stances, such as a recent hypoglycemic
event, having disproportionately more
participants above the intensification
threshold should have resulted in greater
treatment intensification at the 1-year
visit.
Kaplan-Meier (Fig. 3) and Cox regres-
sion analyses (Table 2) show that the
effect of intensive treatment differed
markedly among the HGI subgroups.
For example, if we ignore HGI, the event
rate for primary outcomes was not sig-
nificantly different (P = 0.09) between
the intensive (9.8%) and standard
(10.7%) treatment groups (Table 2 and
Fig. 3A). A statistically significant interaction
was detected between treatment and
HGI (P = 0.0091). Subsequent HGI sub-
group analysis showed that intensive
treatment reduced primary outcomes
by 25% (P = 0.02) in the lowHGI subgroup
and by 23% (P = 0.02) in themoderate HGI
subgroup (Table 2 and Fig. 3B). In contrast,
primary outcomes in the high HGI sub-
group were not significantly different
between the standard and intensive
glycemia treatment groups (P = 0.20).
Ignoring HGI again, total mortality
(Table 2 and Fig. 3C) was significantly
greater (P = 0.02) in the intensive treat-
ment group (7.7%) compared with the
standard treatment group (6.3%). There
was no interaction between treatment
and HGI (P = 0.22). HGI subgroup analy-
sis showed that although intensive
treatment significantly increased total
mortality by 41% (P = 0.02) in the high
HGI subgroup, it had no effect on
mortality in the moderate or low HGI
subgroups compared with standard
treatment (Table 2 and Fig. 3D).
Figure 2—HbA1c and FPG disparity among HGI subgroups. Mean (6 95% CI) HbA1c (,) and FPG
levels (-) for low, moderate, and high HGI subgroups after 1 year of standard (A) or intensive (B)
glycemia treatment. For each panel, HbA1c or FPG values with different superscripts (a, b, c) are
significantly different (P, 0.05). The dotted lines denote protocol-mandated HbA1c treatment-
intensification thresholds.
Figure 3—Kaplan-Meier curves for primary outcomes, total mortality, and hypoglycemia re-
quiring any assistance. Proportions of participants free of the specified outcome over time
are compared between standard and intensive treatment groups (panels A, C, D) and among
the HGI subgroups (panels B, D, F). Standard treatment is depicted by orange dashed lines and
intensive treatment by solid purple lines. Low, moderate, and high HGI subgroups have green,
blue, or red lines, respectively.
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Ignoring HGI once more, hypoglyce-
mia requiring any assistance was more
than threefold greater (P, 0.001) in the
intensive treatment group compared
with the standard treatment group (Ta-
ble 2 and Fig. 3E). HGI subgroup analysis
showed that the incidence of hypogly-
cemia was progressively higher in the
low, moderate, and high HGI subgroups
in the intensive (14.5, 16.8, and 18.8%,
respectively) and standard (3.7, 4.5, and
7.5%, respectively) glycemia treatment
groups (Table 2 and Fig. 3F). Results
were similar for hypoglycemia requiring
medical assistance. Sensitivity analyses
that included other intervention assign-
ments as stratifying factors in the Cox
models, rather than as covariates,
showed that the estimated HRs for pri-
mary outcomes, total mortality, and hy-
poglycemia remained stable.
CONCLUSIONS
Interindividual variation in HbA1c caused
by factors other than blood glucose con-
centration appears tobepartly hereditary
(21,22) and has been reported in patients
with type 1 diabetes (4–9,23,24), with
type 2 diabetes (12–14,25–27), and with-
out diabetes (28–32). Pediatric patients
with type 1 diabetes with higher HGI
had higher levels of skin advanced gly-
cation end products (33). HbA1c levels
that are persistently lower or higher
than expected among individuals with
similar blood glucose levels have been
detected in studies where blood glucose
was estimated based on FPG (12), self-
monitoredmeanblood glucose (4,8,9,34),
7-point mean blood glucose profile sets
(6,35), continuous glucose monitoring
(7,11), or fructosamine (5,26,27). Unlike
other methods for estimating blood glu-
cose, continuous glucosemonitoring and
fructosamine are relatively free of
sampling bias yet produce similar re-
sults when assessing interindividual
variation in HbA1c.
The present studies indicate that sub-
jects in ACCORD with high HGIs had more
retinopathy and nephropathy at baseline,
as previously reported in theDCCT (6). The
differences in drug use observed between
HGI subgroups at baseline could be re-
lated to the fact that insulin is more likely
to be prescribed for individuals with per-
sistently higher HbA1c (high HGI). Alterna-
tively, different drugs have been shown to
influence the quantitative relationship be-
tween HbA1c and blood glucose concen-
tration (36), which could in turn influence
the HGI. Higher HGI among black ACCORD
participants supports our previous obser-
vation of racial variation in HGI in children
with type 1 diabetes (8). Evidence of clin-
ically significant interindividual variation
in the quantitative relationship between
blood glucose concentration and HbA1c
markedly complicates the use of HbA1c
for the diagnosis and management of di-
abetes, especially in mixed-race popula-
tions (37–42).
Heterogeneity of Treatment Outcomes
Among HGI Subgroups in ACCORD
Our present analyses examine the
ACCORD glycemia trial through a new
lens, namely, the HGI calculated using
FPG and HbA1c measured at baseline.
As previously reported by the ACCORD
investigators, we observed no differ-
ence in primary outcomes between the
standard and intensive treatment
groups despite our use of a slightly dif-
ferent data set (we omitted patients
without HbA1c or FPG at baseline) and
different statistical methods. HGI sub-
group analysis indicated, however, that
intensive treatment actually improved
primary outcomes in low and moderate
HGI participants, a beneficial effect that
was offset and masked by the appar-
ently detrimental effects of intensive
treatment in the high HGI subgroup. Al-
though total mortality was significantly
higher in the intensive treatment group,
HGI subgroup analysis showed that the
higher mortality associated with inten-
sive treatment was restricted to the
Table 2—Risk and adjusted hazard ratios of composite primary outcomes, total mortality, and hypoglycemia by glycemia
treatment group and HGI subgroup
Intensive treatment (I) Standard treatment (S) Adjusted hazard ratio (I/S)
Interaction between
treatment and HGI
HGI subgroup At risk Events % At risk Events % Estimate 95% CI P value P value
Primary outcomesa Overall 4,570 446 9.8 4,555 487 10.7 0.89 0.97–1.02 0.09
Low 1,532 119 7.8 1,509 147 9.7 0.75 0.59–0.95 0.02 0.0091
Moderate 1,515 128 8.4 1,527 161 10.5 0.77 0.61–0.97 0.02
High 1,523 199 13.1 1,519 179 11.8 1.14 0.93–1.40 0.20
Total mortalityb Overall 4,570 350 7.7 4,555 287 6.3 1.21 1.04–1.42 0.02
Low 1,532 97 6.3 1,509 86 5.7 1.08 0.81–1.44 1.00d 0.2240
Moderate 1,515 102 6.7 1,527 92 6.0 1.06 0.80–1.41 1.00d
High 1,523 151 9.9 1,519 109 7.2 1.41 1.10–1.81 0.02d
Hypoglycemiac Overall 4,570 763 16.7 4,555 238 5.2 3.64 3.14–4.21 ,0.001
Low 1,532 222 14.5 1,509 56 3.7 4.27 3.21–5.78 ,0.001 0.0350
Moderate 1,515 254 16.8 1,527 68 4.5 4.32 3.32–5.68 ,0.001
High 1,523 287 18.8 1,519 114 7.5 2.91 2.35–3.63 ,0.001
aFirst occurrence of nonfatal MI, nonfatal stroke, or death from cardiovascular events. Covariates include age, sex, race, education, diabetes
duration, history of smoking, previous CVD, high risk of heart failure, history of arterial stenosis, history of albuminuria, retinopathy at baseline,
estimated glomerular filtration rate, HDL-cholesterol, LDL-cholesterol, and intervention trial (hypertension treatment, intensive vs. standard;
hypertension trial vs. lipid trial; hyperlipidemia treatment, fibrate vs. no fibrate). bDeath from any cause. Covariates include age, sex, race, education,
history of smoking, statin uses, insulin uses, previous CVD, history of albuminuria, history of arterial stenosis, retinopathy at baseline, and
intervention trial (hypertension treatment, intensive vs. standard; hypertension trial vs. lipid trial; hyperlipidemia treatment, fibrate vs. no fibrate).
cSymptomatic, severe hypoglycemia requiring any assistance. Covariates include age, sex, race, education, diabetes duration, living alone or not,
insulin uses, previous CVD, retinopathy at baseline, neuropathy at baseline, and estimated glomerular filtration rate. dBonferroni correction for
multiple comparisons.
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high HGI subgroup. Collectively, these
observations show that HGI identifies
two subpopulations in ACCORD, one
that experiences benefits and one that
experiences harms from the same inten-
sive glucose-lowering strategy.
The risk for hypoglycemia was great-
est in the high HGI subgroup in the stan-
dard and intensive treatment groups.
More high HGI participants remained
above the protocol-mandated HbA1c
treatment thresholds after 1 year of
standard or intensive treatment. De-
spite higher mean HbA1c, high HGI par-
ticipants in both glycemia treatment
groups had mean FPG values after 1
year that were as low as or lower than
those observed in low HGI participants.
Collectively, these observations are con-
sistent with our hypothesis that inten-
sive treatment may have inadvertently
caused high HGI participants to receive
more intensive treatment and could ex-
plain the otherwise paradoxical results
reported by Miller et al. (3).
Clinical Implications
The twin goals of diabetes management
are to keep blood glucose levels low
enough to limit the development of
long-term diabetes complications but
high enough to avoid hypoglycemia. After
the ACCORD trial reported that intensive
treatment increased mortality and hypo-
glycemia, the American Diabetes Associ-
ation (ADA) recommended that HbA1c
treatment goals for individual patients
should be personalized according to char-
acteristics such as age and frequency of
hypoglycemia, while also reiterating that
loweringHbA1c generally helps prevent or
delay long-term complications (43). Our
observations of markedly different out-
comes in the different HGI subgroups in
response to intensive treatment strongly
supports the ADA recommendation for
more personalized diabetesmanagement
and suggests that HGI could be used to
help individualize treatment goals.
Exactly how the results of this study
might be used to reinterpret other clin-
ical trials or how the results might be
applied in future trial designs or in clin-
ical practice remains to be determined.
One reason is that ACCORD participants
were older than the general public and
selected for elevated risk for CVD. This
could explain why the baseline regres-
sion equation in ACCORD is markedly
different from the linear regression
equations reported by studies such as
the A1C-Derived Average Glucose
(ADAG) study (44). As such, the results
may not be generalizable to other clin-
ical trials or to the general population
with diabetes and we cannot recom-
mend the use of the ACCORD regression
equation in other populations. Further-
more, only one other study has used
FPG to assess the HGI in patients with
type 2 diabetes, and these results were
only reported in a meeting abstract
(12). All other prior HGI and glycation
gap studies in patients with diabetes
used some estimate of mean blood glu-
cose or fructosamine. Additional stud-
ies of HGI in other clinical trials could
help determine how best to use the
HGI in clinical practice.
Conclusion
Intensive treatment to a low HbA1c tar-
get of less than 6% (42 mmol/mol) can-
not be recommended for all patients
with type 2 diabetes because primary
cardiovascular outcomes, total mortal-
ity, and hypoglycemia were all adversely
affected in high HGI participants in
ACCORD. Further studies should deter-
mine if the observed beneficial effects of
intensive treatment on primary out-
comes in low and moderate HGI partic-
ipants outweigh any detrimental effects
that might be caused by the increase in
hypoglycemia associated with intensive
treatment. Our results confirm that
HbA1c is not a one-size-fits-all indicator
of blood glucose concentration and sug-
gest that failure to take this into account
can result in suboptimal diabetes care.
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